Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. develops and commercializes medical-device and therapy-enabling systems for precise navigation to the brain and spine. Its recurring news includes updates on the FDA-cleared and CE-marked ClearPoint Neuro Navigation System, SmartFrame navigation platform, SmartFlow Neuro Cannula, Velocity Alpha MR High Speed Surgical Drill System, and services that support controlled CNS delivery for cell and gene therapy programs.
Company announcements also cover financial results, product clearances and international regulatory approvals, preclinical development services, biopharma and academic partnerships, and integration of the completed IRRAS Holdings acquisition, which expanded the portfolio into neurocritical care and IRRAflow-related products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ClearPoint Neuro (Nasdaq: CLPT), a global therapy-enabling platform company focused on brain navigation and delivery, has announced its participation in the B. Riley Securities 2023 Institutional Investor Conference. The company's management team is scheduled to present on Wednesday, May 24, 2023, at 8:15 a.m. Pacific Time.
This conference provides an opportunity for ClearPoint Neuro to showcase its innovative technologies and business strategies to institutional investors. As a leader in brain-focused therapies, the company's presentation is likely to generate significant interest among attendees and potential investors in the medical technology sector.
Summary not available.
Summary not available.
Summary not available.